Expert Insight and Practical Guidance on Microsatellite Instability in Gastrointestinal Cancers
  • CME

Review expert recommendations and key evidence for the use of immune checkpoint inhibitors in MSI-H gastrointestinal cancers in an expert panel discussion led by John L. Marshall, MD, along with Tim F. Greten, MD, and Yelena Y. Janjigian, MD. This program is divided into 4 segments. After clicking the Launch buttons below, the player will open in a new window. If it does not appear, please disable your pop-up blocker and try again. After reviewing all segments, click the Claim Credit button to the right to complete the CME posttest and evaluation.
John L. Marshall, MD
Program Director
Tim F. Greten, MD
Yelena Y. Janjigian, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: December 22, 2017 Expiration: December 21, 2018
Multimedia Expert Insight and Practical Guidance on Microsatellite Instability in Gastrointestinal Cancers
This program is divided into four segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Part 1: Introduction (2 minutes)
Introduction and baseline assessment.
Launch Part 1: Introduction (2 minutes)
Part 2: Does Immunotherapy Work in GI Cancers? (45 minutes)
The panel of experts discuss MSI/MMR testing and interpretation, current indications, and expert recommendations for using immune checkpoint inhibitors in gastrointestinal cancers with supporting evidence, and management of immune-related adverse events. Case discussion of a patient with metastatic colorectal cancer.
Launch Part 2: Does Immunotherapy Work in GI Cancers? (45 minutes)
Part 3: Immune Checkpoint Inhibition in Gastric Cancer and Future Directions (12 minutes)
The panel explores current and emerging biomarkers of response to immune checkpoint inhibitors in gastric cancer and case discussion of a patient with chemotherapy-refractory gastric cancer.
Launch Part 3: Immune Checkpoint Inhibition in Gastric Cancer and Future Directions (12 minutes)
Part 4: Conclusion (5 minutes)
Final thoughts from the panel on immunotherapy in gastrointestinal cancers and future directions.
Launch Part 4: Conclusion (5 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal therapies for patients with MSI-H gastrointestinal cancers and be prepared to integrate newer therapies as they emerge
  • Screen patients with gastrointestinal cancers for mismatch repair deficiencies, including microsatellite instability

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Merck & Co., Inc.

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD has disclosed that he has received consulting fees and funds for research from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho.

Faculty

Tim F. Greten, MD

National Cancer Institute
Bethesda, Maryland
Former Associate Professor of Medicine
Department of Gastroenterology and Hepatology
Hannover Medical School
Hannover, Germany

Tim F. Greten, MD, has no real or apparent conflicts of interest to report.
Yelena Y. Janjigian, MD

Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Yelena Y. Janjigian, MD, has disclosed that she has received funds for research support from Bayer, Bristol-Myers Squibb, Lilly, BI, Amgen, Roche, and Genentech and consulting fees from Lilly and Pfizer.

Staff

Terrence Fagan

Associate Managing Editor

Terrence Fagan has no real or apparent conflicts of interest to report.
Krista Marcello

Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, surgeons, pathologists, and other healthcare providers who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to impart participant competence to encourage appropriate testing for MSI and utilization of MSI test results to guide the clinical care of patients with gastrointestinal cancers.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 22, 2017, through December 21, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Watch a CME/CE-certified Webcast of an ASCO 2018 symposium where John L. Marshall, MD, leads an expert panel reviewing the top 10 oncology biomarkers.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: July 10, 2018 Expiration: July 9, 2019

Expert commentary from Manish A. Shah, MD, on recent developments in targeting cancer stem cells in gastrointestinal cancers, including data from ASCO 2018.

Manish A. Shah, MD Released: June 28, 2018

Downloadable PDF with clinical insights, approved agents, and available assays for MSI-high/MMR-deficient colorectal cancer and other solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Released: June 13, 2018

Final phase III KEYNOTE-061 data on efficacy and safety of second-line pembrolizumab vs paclitaxel in gastric/GEJ cancer from ASCO 2018 reported by Clinical Care Options (CCO).

Released: June 12, 2018

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?